Astrazeneca Share News (AZN)

The high growth companies that could re-rate in a recession

STOXX 600 up 0.6%, techs among big gainers

*

AstraZeneca's diabetes combination treatment approved in China

(Alliance News) - AstraZeneca PLC on Tuesday said its Xigduo XR combination treatment has received approval in China for type-2 diabetes.

EU committee recommends expanded approval for AstraZeneca's Soliris

(Alliance News) - AstraZeneca PLC on Monday said Soliris has been recommended for marketing authorisation in the EU for expanded use in generalised myasthenia gravis, gMG.

Novo Nordisk says EMA raised safety signal on drugs including semaglutide

Signal included drugs from Eli Lilly, AstraZeneca, Sanofi

*

Novo Nordisk shares slip on EMA drug safety signal

COPENHAGEN, June 22 (Reuters) - Novo Nordisk said on Thursday the European Union's drug watchdog had last month raised a thyroid cancer safety signal for several of its drugs including semaglutide, the active ingredient in its popular diabetes and obesity drugs, Ozempic and Wegovy.

Lab crunch: British science has nowhere to go

OXFORD, England, June 20 (Reuters) - For Ros Deegan, the thrill of raising $100 million to expand a biotech firm among the dreaming spires of Oxford was soon tempered: unable to find a bigger laboratory, she routinely had to work at home.

London stocks lag as miners slip; AstraZeneca weighs

AstraZeneca down on report of China business spin off plan

*

Adding equities on disinflation, short squeeze risk - TS Lombard

STOXX 600 down 0.6%

*

China spin-off may allow AstraZeneca to avoid "regulatory clampdown"

(Alliance News) - The Financial Times reported on Monday that AstraZeneca PLC has drafted plans to separate its China business amid geopolitical tensions.

More to come as bear capitulation drives recent risk rally

STOXX 600 down 0.5%

*

AstraZeneca planning spinoff of China business - report

(Sharecast News) - AstraZeneca has reportedly drawn up plans to break out its China business and list it separately in Hong Kong as a way to shelter the company against mounting geopolitical tensions.

Cautious start for Europe

STOXX 600 down 0.6%

*

LONDON MARKET OPEN: Stocks falter amid weaker outlook for China

(Alliance News) - Stock prices in London opened lower on Monday, ahead of more interest rate decisions, and amid fears for China's slowing economic recovery.

LONDON BRIEFING: Severn Trent deal sized up by CMA; Coca-Cola HBC buys

(Alliance News) - Stocks in London are called lower on Monday, ahead of more central bank decisions, while a meeting between US Secretary of State Antony Blinken and his Chinese counterpart put relations between the two nations back under the spotlight.

PRESS: AstraZeneca drafts plan to spin-off in China - FT

(Alliance News) - AstraZeneca PLC has drafted plans to separate its China business amid geopolitical tensions, the Financial Times reported on Monday.